Anhui Fengyuan Pharmaceutical Co., Ltd.

Symbol: 000153.SZ

SHZ

8.55

CNY

Market price today

  • 17.7110

    P/E Ratio

  • 0.1358

    PEG Ratio

  • 2.84B

    MRK Cap

  • 0.01%

    DIV Yield

Anhui Fengyuan Pharmaceutical Co., Ltd. (000153-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ). Companys revenue shows the average of 1464.253 M which is 0.206 % gowth. The average gross profit for the whole period is 433.999 M which is 0.211 %. The average gross profit ratio is 0.311 %. The net income growth for the company last year performance is 0.031 % which equals 0.332 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Anhui Fengyuan Pharmaceutical Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.017. In the realm of current assets, 000153.SZ clocks in at 1902.911 in the reporting currency. A significant portion of these assets, precisely 319.905, is held in cash and short-term investments. This segment shows a change of -0.094% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 575.808, if any, in the reporting currency. This indicates a difference of 1.596% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 194.964 in the reporting currency. This figure signifies a year_over_year change of -0.127%. Shareholder value, as depicted by the total shareholder equity, is valued at 1889.41 in the reporting currency. The year over year change in this aspect is 0.093%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 984.777, with an inventory valuation of 573.58, and goodwill valued at 7.92, if any. The total intangible assets, if present, are valued at 285.63. Account payables and short-term debt are 746.11 and 492.8, respectively. The total debt is 687.76, with a net debt of 367.86. Other current liabilities amount to 10.19, adding to the total liabilities of 2472.49. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997

balance-sheet.row.cash-and-short-term-investments

1104.98319.9353.1251.3
282.3
360.6
311.4
275.9
176.5
164.9
167.9
308.9
65.7
57.4
96.4
107.3
109.7
59.5
81.4
159.9
128.2
59
95
208.1
381.2
4.4
1.7
3.3

balance-sheet.row.short-term-investments

-860.53-213.480.7-226.9
7
9.9
7.8
13.5
20.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

4181.1984.8925.9839.2
887.9
864.7
811.5
809.5
719
497.4
554.6
423.7
382.8
349.2
318.6
397.5
367.3
392.4
511.3
261.2
259.3
173
129.3
101.3
2.5
2.2
2
2.5

balance-sheet.row.inventory

2298.35573.6699.1569.5
527.2
486.8
461
402.3
274.4
270.2
253.9
212.3
201.6
179.2
153.1
132.7
140.5
111.1
70.3
77.7
45.2
22.1
13.5
30.3
24.8
32.7
20.6
4.6

balance-sheet.row.other-current-assets

155.2724.799.234.8
41
27.1
4.3
8.3
10.4
11.7
-28.4
-23.5
-28.7
-23.4
-21.6
-61.9
-55.3
-71.1
-147.1
-32.3
-39.7
-13.9
-13.9
-12.1
55.6
36.1
27.7
15.4

balance-sheet.row.total-current-assets

7739.71902.92077.41694.8
1738.3
1739.2
1588.2
1496
1180.3
944.2
948
921.5
621.5
562.4
546.5
575.6
562.2
491.8
515.9
466.5
393
240.2
223.9
327.6
464.1
75.3
51.9
25.8

balance-sheet.row.property-plant-equipment-net

6019.731513.91461.71223.5
1044.1
877.1
806.6
817.3
856.2
906.4
871.2
719.7
612.1
544.9
536.6
509
484.3
475.6
495.5
462.6
450
447.1
408.5
348.2
169.2
57.8
56.5
25.8

balance-sheet.row.goodwill

31.687.97.97.9
11.5
11.5
11.5
11.5
11.5
11.5
11.5
11.5
11.5
11.5
11.5
11.5
7.9
7.9
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

1126.56285.6244.9225.8
208.8
171.3
166.5
136.2
138.5
177.1
174.6
172.1
168.2
165.2
148.1
67.8
69.4
69.4
15.7
19.9
23.1
24.6
27
8.4
0.3
0.2
0
0

balance-sheet.row.goodwill-and-intangible-assets

1158.24293.5252.8233.7
220.3
182.8
178
147.8
150
188.6
186.2
183.7
179.7
176.7
159.6
79.3
77.3
77.3
15.7
19.9
23.1
24.6
27
8.4
0.3
0.2
0
0

balance-sheet.row.long-term-investments

2388.93575.8566.8556.4
312.7
423.1
212.5
117.8
109.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

213.460.24037.5
21
21.6
18
13.8
10.4
6.3
5.6
6.3
7.1
5.8
5.8
5.7
6.1
8.4
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

162.134570.670.4
299.9
315.8
204.8
175
183.9
259.8
226.6
149.9
30.1
28.4
27.3
35.9
35.7
35.5
38.5
143.7
29.9
25
25
25.3
1.1
1.3
1.9
7.3

balance-sheet.row.total-non-current-assets

9942.452488.42391.82121.6
1897.9
1820.4
1419.8
1271.8
1310.1
1361.1
1289.6
1059.6
829
755.8
729.3
629.9
603.3
596.8
549.7
626.2
502.9
496.7
460.5
381.9
170.7
59.3
58.4
33.1

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

17682.154391.34469.23816.3
3636.2
3559.6
3008
2767.7
2490.4
2305.3
2237.5
1981
1450.5
1318.2
1275.8
1205.5
1165.6
1088.6
1065.6
1092.7
895.9
736.9
684.4
709.5
634.8
134.6
110.3
58.9

balance-sheet.row.account-payables

2940.77746.1722.7612.9
712.3
962.3
781.5
557.4
439.4
282.7
280.3
203.9
176.6
163.6
148.2
149.4
221.2
145.4
100.5
97.2
64.1
32.3
27.6
26.4
16.9
14.8
15.3
9

balance-sheet.row.short-term-debt

2171.78492.8598.4501.1
582.6
492.8
367.2
509.8
530
493
463.2
275.5
279.5
258.2
231.4
211.4
218.5
174.8
253.7
308
171.5
75
40
70
44
29.6
17.4
10.5

balance-sheet.row.tax-payables

201.4849.968.143.5
45.4
40.5
36.5
44.4
38.8
13.3
4.9
7.2
-3.4
-1.5
8.3
9.1
5.3
12.2
8.9
-5.3
-2.4
-1.9
-0.5
5.3
10.2
3.1
2.7
2

balance-sheet.row.long-term-debt-total

944.12195189.6114
27
105.1
0
0
43
59.4
67.8
197
60
0
40
70
0.9
0.9
0
0
0
0
3.5
0
5
8
13
10.1

Deferred Revenue Non Current

795.47238151.9150.9
77.3
78.9
59
38.7
25.6
17.2
18.6
52.1
0
0
0
-70
0
0
0
0
0
0
0
0
-5
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

104.89---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

37.2110.2766.315.9
13.6
64.7
454.7
48.8
47.5
23.8
35.8
28
26.3
26.5
17
25.4
16.8
8.4
13.8
9
10.1
13.3
8.1
15.3
0.6
5.6
1.2
5.3

balance-sheet.row.total-non-current-liabilities

1844.48458.9369.8338.2
123.1
197.8
76.2
57.6
86.5
143.2
152
271.7
63.8
3.3
43
72.5
3.4
3.4
0.9
0.9
0.9
0.9
3.5
0
11.2
8
13
10.1

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

74.5520.220.728
38.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

10056.972472.52714.52258.6
2188.2
2232.5
1716.2
1547.3
1337.6
1121
1090.6
926.7
675.5
553
522
526.8
511.5
449.7
445.1
493.1
304.9
160.9
123.5
173.3
102.3
81.6
66
34.9

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

1328.27332332.1312.1
312.1
312.1
317.1
317.1
312.1
312.1
312.1
312.1
260
260
260
260
260
260
260
260
130
130
65
65
65
40
40
20.6

balance-sheet.row.retained-earnings

3532.26888.7764.4629.3
518.9
417.2
370.2
312
246.7
250
217.6
176.6
180.5
188.6
179.5
140.7
118.6
104.9
88.6
68.8
61.1
53
53.8
33.1
29.8
7.5
0.1
2.4

balance-sheet.row.accumulated-other-comprehensive-income-loss

919.4353.1595.2112.2
107.9
120.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

1733.96615.536.8474.6
474.6
474.6
601.4
591.3
593.9
588.6
582.7
524.9
293.7
274.9
274.1
270.8
269
268.5
266.8
265.8
394.5
393
442.1
437
436.6
4.4
3.2
1

balance-sheet.row.total-stockholders-equity

7513.921889.41728.51528.2
1413.5
1324.3
1288.7
1220.5
1152.8
1150.7
1112.4
1013.6
734.2
723.5
713.5
671.5
647.6
633.4
615.4
594.6
585.6
576
560.9
535.1
531.4
51.9
43.3
24

balance-sheet.row.total-liabilities-and-stockholders-equity

17682.154391.34469.23816.3
3636.2
3559.6
3008
2767.7
2490.4
2305.3
2237.5
1981
1450.5
1318.2
1275.8
1205.5
1165.6
1088.6
1065.6
1092.7
895.9
736.9
684.4
709.5
634.8
134.6
110.3
58.9

balance-sheet.row.minority-interest

111.2629.426.329.5
34.5
2.8
3.1
0
0
33.6
34.5
40.7
40.9
41.8
40.3
7.2
6.5
5.5
5.1
5
5.5
0
0
1.1
1.1
1.1
1.1
1.1

balance-sheet.row.total-equity

7625.181918.81754.81557.7
1448
1327.1
1291.8
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

17682.15---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

1528.4362.4371.5329.5
319.7
433
220.3
131.3
129.7
107.9
101
25
25
25
25
34.2
34.2
34.2
36.9
141.7
28.6
25
25
25.3
0.8
1.3
1.9
7.3

balance-sheet.row.total-debt

3115.9687.8788615.1
609.6
597.9
367.2
509.8
573
552.4
531
472.5
339.5
258.2
271.4
281.4
218.5
174.8
253.7
308
171.5
75
43.5
70
49
37.6
30.4
20.6

balance-sheet.row.net-debt

2010.92367.9434.8363.8
334.3
247.2
63.6
247.4
416.5
387.5
363.1
163.6
273.8
200.8
175
174.1
108.8
115.3
172.3
148.1
43.3
16
-51.5
-138.2
-332.2
33.2
28.7
17.3

Cash Flow Statement

The financial landscape of Anhui Fengyuan Pharmaceutical Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.713. The company recently extended its share capital by issuing 0, marking a difference of -0.026 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 261.41 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -99392650.670 in the reporting currency. This is a shift of -0.336 from the previous year. In the same period, the company recorded 121.7, 308.31, and -804.3, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -57.48 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 599.51, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999

cash-flows.row.net-income

160.27150.9109.5102.1
80.6
60.7
65.3
45.7
31.5
41.1
27.2
18.1
9.9
40.5
23.7
15.2
5.9
22.1
9.3
10
18.1
25.8
24.8
26.3
8.6

cash-flows.row.depreciation-and-amortization

98.78121.776.870.9
70.6
74.8
74.8
68.8
63.2
68.8
58.8
52.4
50.2
49.6
44.8
41.2
39.3
30.1
32.1
27.8
23.4
15.2
9.4
5.5
3.7

cash-flows.row.deferred-income-tax

-11.32-5.7-10.35.6
-7.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

18.885.710.3-5.6
7.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-112.36121.5-4.673.8
-127.9
44.2
-142.3
-71
-83.7
-124.7
-61.4
-51.6
-19.3
-38
-46.2
-25.3
-21
-6.7
-21.6
-56.4
-50.5
-38.7
-19.8
-6.6
-14.3

cash-flows.row.account-receivables

-238.77-89.3-114.144.8
-7.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

126.41-44.9-42.3-40.7
-23.3
-58.5
-129.4
-5.5
-16.3
-41.6
-12.1
-19.8
-26.4
-20.2
8.7
-28.8
-41.3
7.1
-32.2
-4.5
-9
-0.2
-6.4
7.9
-12.1

cash-flows.row.account-payables

0261.4138.8-44.8
7.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-5.712.9114.5
-104.6
102.7
-12.9
-65.4
-67.4
-83.1
-49.3
-31.7
7
-17.8
-54.9
3.5
20.3
-13.8
10.6
-51.9
-41.5
-38.5
-13.4
-14.5
-2.2

cash-flows.row.other-non-cash-items

115.1245.856.246
43
53.9
54.5
34.7
34.5
25.3
-95
26.7
14.2
3
10.1
18.7
31.1
-9.2
15.1
6.9
-2.5
8.2
9.1
0.7
3

cash-flows.row.net-cash-provided-by-operating-activities

250.48000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-153.03-81.8-157.4-190.7
-145.6
-84.6
-48
-22.2
-50.3
-175.9
-113.9
-95.1
-69.9
-89.7
-74.4
-31.6
-35.2
-136.7
-35.7
-47
-56.6
-91.4
-190.2
-117.8
-4.6

cash-flows.row.acquisitions-net

7.94-302.714.3
145.6
1.8
1
-34.7
0
0
0
95.1
0
100.5
-12.5
0
1.7
-1.7
22
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-85-29-1-31.9
-221.8
-104.8
-27.7
-49.2
0
0
0
-7.2
0
-0.2
74.6
0
-2.6
-0.2
-166.6
-16.6
0
0
-25
0
0

cash-flows.row.sales-maturities-of-investments

0.155.77.2133.1
4.4
5.7
39.9
35.1
6.9
11
3.7
3.7
3.7
36.7
6.7
5.7
41
70
54.1
0
0
0
0
0
0

cash-flows.row.other-investing-activites

-76.6308.30.40.4
-145.6
20
0
13.2
0
0
60.2
-95.1
0
-89.7
-74.4
1
25.5
25.2
1.7
52.1
2.2
-1.8
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-229.62-99.4-149.7-84.9
-363
-162
-34.7
-57.8
-43.4
-164.9
-50.1
-98.5
-66.2
-42.5
-80
-24.8
30.5
-43.4
-124.5
-11.5
-54.5
-93.2
-215.2
-117.8
-4.6

cash-flows.row.debt-repayment

-588.23-804.3-942.9-1157.2
-845
-780.7
-685
-695.4
-588.6
-329
-297.9
-278.2
-231.4
-231.4
-238.2
-174.8
-266.1
-389.1
-171.5
-75
-83.5
-57
-97
-28.5
-11.4

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

-0.35000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-62.48-57.5-25.6-38.4
-51.7
-31.7
-34.4
-60.4
-30.8
-32
-50.8
-20.9
-16.2
-14.9
-17.7
-18.4
-16.2
-17.1
-15.2
-6.5
-4.7
-16.9
-7.4
-2.6
-2.9

cash-flows.row.other-financing-activites

358.44599.5862.5985.8
1183.8
800.5
767.4
708
610
374.4
712.1
359.5
219.7
222.9
301.1
218.5
174.8
334.8
308
173.9
118.2
43.5
123
499.9
20.6

cash-flows.row.net-cash-used-provided-by-financing-activities

55.59-262.3-106-209.8
287.1
-11.9
48
-47.8
-9.5
13.4
363.4
60.4
-27.9
-23.4
45.2
25.3
-107.5
-71.4
121.3
92.4
30
-30.4
18.6
468.8
6.3

cash-flows.row.effect-of-forex-changes-on-cash

0.210.1-0.3-0.6
0
0.3
-0.2
0.1
0.1
0
0.2
0
0
0
0
-0.1
-0.1
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

76.6678.4-18.2-2.5
-9.7
60
65.5
-27.3
-7.3
-141
243.2
7.6
-39
-10.8
-2.4
50.2
-21.9
-78.5
31.7
69.2
-36
-113.1
-173.1
376.8
2.7

cash-flows.row.cash-at-end-of-period

1001.66344.7234.6252.8
255.3
265
205
139.5
160.6
167.9
308.9
65.7
57.4
96.4
107.3
109.7
59.5
81.4
159.9
128.2
59
95
208.1
381.2
4.4

cash-flows.row.cash-at-beginning-of-period

925266.3252.8255.3
265
205
139.5
166.8
167.9
308.9
65.7
58.1
96.4
107.3
109.7
59.5
81.4
159.9
128.2
59
95
208.1
381.2
4.4
1.7

cash-flows.row.operating-cash-flow

250.48440237.9292.8
66.2
233.6
52.4
78.2
45.5
10.5
-70.3
45.7
55.1
55
32.4
49.8
55.3
36.3
34.9
-11.7
-11.5
10.5
23.6
25.9
1

cash-flows.row.capital-expenditure

-153.03-81.8-157.4-190.7
-145.6
-84.6
-48
-22.2
-50.3
-175.9
-113.9
-95.1
-69.9
-89.7
-74.4
-31.6
-35.2
-136.7
-35.7
-47
-56.6
-91.4
-190.2
-117.8
-4.6

cash-flows.row.free-cash-flow

97.45358.280.5102
-79.4
149
4.4
56
-4.8
-165.3
-184.2
-49.4
-14.8
-34.7
-42
18.2
20.1
-100.4
-0.8
-58.7
-68.1
-80.9
-166.7
-91.9
-3.6

Income Statement Row

Anhui Fengyuan Pharmaceutical Co., Ltd.'s revenue saw a change of 0.068% compared with the previous period. The gross profit of 000153.SZ is reported to be 1099.15. The company's operating expenses are 857.07, showing a change of -4.546% from the last year. The expenses for depreciation and amortization are 121.7, which is a -0.205% change from the last accounting period. Operating expenses are reported to be 857.07, which shows a -4.546% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.055% year-over-year growth. The operating income is 213.25, which shows a 0.055% change when compared to the previous year. The change in the net income is 0.031%. The net income for the last year was 159.29.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997

income-statement-row.row.total-revenue

4189.994275.440043501.7
3321.2
3238.1
3013.4
2578.1
2033.7
1554.3
1698.9
1529.9
1657.8
1516.5
1074.2
955.7
873.8
703.8
521.3
441.2
280.5
179.1
157.9
159.2
114.1
57.2
49.6
44.1

income-statement-row.row.cost-of-revenue

3142.573176.32873.72447.4
2170
2002.6
1839.7
1789.2
1492.5
1136.7
1248.7
1131.3
1276.8
1213.2
788.8
693.5
640.3
527.9
392.3
328.8
205.7
110.2
86
80.7
69.5
35.6
31.5
28.2

income-statement-row.row.gross-profit

1047.421099.11130.31054.3
1151.2
1235.5
1173.7
788.9
541.2
417.6
450.2
398.6
380.9
303.3
285.3
262.2
233.6
175.9
129
112.4
74.9
68.9
72
78.5
44.7
21.6
18.1
15.9

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

64.97---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

34.67---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

543.4---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

1.431.6117.7103.7
99
96.3
0.5
0.5
76
11.9
10.5
12.8
12.2
6.3
13.7
5.3
0.7
0.8
27
2.7
0.3
1.4
2
1.1
1.3
0.2
0
0

income-statement-row.row.operating-expenses

793.23857.1897.9863.7
990.3
1078.2
1034.8
655.7
449.2
357.2
384.4
347.3
343.7
283.2
242.6
228.5
196.8
132
108.4
91.4
55.5
45.9
37.5
48.8
13.7
10.2
8.1
8

income-statement-row.row.cost-and-expenses

3935.84033.43771.63311.1
3160.3
3080.8
2874.5
2445
1941.7
1493.9
1633.2
1478.6
1620.6
1496.4
1031.4
922
837.1
659.9
500.6
420.2
261.2
156.1
123.5
129.4
83.2
45.8
39.6
36.2

income-statement-row.row.interest-income

10.218.75.43.1
3.7
3.9
4.1
2.5
2.2
2.1
2.9
3
0.6
0.5
0.9
3.5
1.3
1.6
3.9
1.9
3.2
4.4
3
5.1
1.8
0
0
0

income-statement-row.row.interest-expense

31.8433.932.938.6
39.5
37.1
31
32.4
28.5
31.9
32.1
22.1
20.6
16.3
14.5
17.7
18.4
16.2
19.6
14.6
6.5
3.3
2.2
3.7
2.5
2.1
1.8
2.2

income-statement-row.row.selling-and-marketing-expenses

543.4---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

1.431.60.23.7
-47.8
-4.2
-45.8
-36.5
-25.4
-18.3
-9.4
-10.2
-11.9
-6.3
9.8
-1.6
-16.2
-28.1
15.6
-11.1
-4.4
3.6
-0.8
1.9
-0.1
-2.6
-2.3
-2.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

1.431.6117.7103.7
99
96.3
0.5
0.5
76
11.9
10.5
12.8
12.2
6.3
13.7
5.3
0.7
0.8
27
2.7
0.3
1.4
2
1.1
1.3
0.2
0
0

income-statement-row.row.total-operating-expenses

1.431.60.23.7
-47.8
-4.2
-45.8
-36.5
-25.4
-18.3
-9.4
-10.2
-11.9
-6.3
9.8
-1.6
-16.2
-28.1
15.6
-11.1
-4.4
3.6
-0.8
1.9
-0.1
-2.6
-2.3
-2.4

income-statement-row.row.interest-expense

31.8433.932.938.6
39.5
37.1
31
32.4
28.5
31.9
32.1
22.1
20.6
16.3
14.5
17.7
18.4
16.2
19.6
14.6
6.5
3.3
2.2
3.7
2.5
2.1
1.8
2.2

income-statement-row.row.depreciation-and-amortization

53.36126.3158.9125.4
70.9
108.5
74.8
74.8
68.8
63.2
68.8
58.8
52.4
50.2
49.6
44.8
41.2
39.3
30.1
32.1
27.8
23.4
15.2
9.4
5.5
3.7
2.3
2.4

income-statement-row.row.ebitda-caps

267.41---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

214.06213.3202.1146
185.9
124.1
92.5
96.1
62.9
30.2
45.9
28.5
14.6
7.9
39.6
26.9
19.9
15
12.4
11.2
16.5
24.1
31.7
30.6
29.5
8.6
7.8
5.5

income-statement-row.row.income-before-tax

215.48214.9202.3149.7
138.1
119.9
93.1
96.7
66.6
42.1
56.4
41.1
25.3
13.8
52.6
32.1
20.6
15.8
37.8
11.9
15.8
26.6
33.7
31.7
30.9
8.8
7.8
5.5

income-statement-row.row.income-tax-expense

57.4757.651.440.3
36
39.3
32.4
31.3
20.8
10.6
15.3
14
7.2
3.9
12.1
8.4
5.4
9.9
15.7
2.6
5.8
8.5
7.9
6.9
4.6
0.1
0.1
1

income-statement-row.row.net-income

160.27159.3154.4123
103.7
80.9
60.9
65.3
45.8
32.4
41
27.3
19
9.9
41.6
23
14.2
5.6
22
9
9.6
18.1
25.8
24.8
26.3
8.6
7.7
4.5

Frequently Asked Question

What is Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ) total assets?

Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ) total assets is 4391320148.000.

What is enterprise annual revenue?

The annual revenue is 2172036791.000.

What is firm profit margin?

Firm profit margin is 0.250.

What is company free cash flow?

The free cash flow is 0.294.

What is enterprise net profit margin?

The net profit margin is 0.038.

What is firm total revenue?

The total revenue is 0.051.

What is Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ) net profit (net income)?

The net profit (net income) is 159285567.000.

What is firm total debt?

The total debt is 687763094.000.

What is operating expences number?

The operating expences are 857067068.000.

What is company cash figure?

Enretprise cash is 335906057.000.